Clinical Trial Update: A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating SANGUINATE to reduce delayed graft function after kidney transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Delayed Graft Function After Kidney Transplantation

Drugs mentioned

• SANGUINATE

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Delayed Function of Renal Transplant | Phase 2 | Status: WITHDRAWN